Es Cushing Age Appropriate Vaccinations

---
name: es-cushing-age-appropriate-vaccinations
description: This skill recommends discussing and offering age-appropriate vaccinations (influenza, herpes zoster, pneumococcal) to patients with Cushing’s syndrome due to increased infection risk. Use when reviewing preventive care for a CS patient; triggers include discussing preventive care, vaccination status, or infection risk in a CS patient.
---

# Age-Appropriate Vaccinations for Cushing's Syndrome Patients

## STEP 1 — Gather Information
Confirm diagnosis of Cushing’s syndrome; review current vaccination status and age; note contraindications (e.g., severe immunocompromise for live vaccines). → Proceed to assess vaccine needs.

## STEP 2 — Rule In / Rule Out
Is Cushing’s syndrome confirmed? If no, stop; if yes, proceed to age‑based vaccine stratification.

## STEP 3 — Classify or Stratify
Age‑based recommendations:  
- Influenza: inactivated vaccine annually for all ages.  
- Herpes zoster: recombinant subunit vaccine (Shingrix) for age ≥50 years.  
- Pneumococcal: PCV20 alone, or PCV15 followed by PPSV23 per CDC schedule for age ≥19 years with immunocompromising condition (including CS).  

## STEP 4 — Decide
Offer and administer indicated vaccines; document administration; schedule next influenza dose and recall for series completion if needed.

## Clinical Guardrails / Mimics / Pitfalls
Do not delay vaccination due to active hypercortisolism; avoid live attenuated influenza vaccine (LAIV) in severely immunocompromised patients; herpes zoster and pneumococcal vaccines are inactivated/recombinant and safe. Vaccination does not replace infection prophylaxis or treatment.

## Concrete Clinical Example
A 58‑year‑old woman with active adrenal adenoma‑related Cushing’s syndrome presents for routine follow‑up. She lacks this season’s influenza vaccine and has never received herpes zoster or pneumococcal vaccines. Clinician confirms CS, notes age ≥50, offers inactivated influenza vaccine, recombinant herpes zoster vaccine (Shingrix), and pneumococcal PCV20. Documents and schedules annual flu recall.

**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, https://doi.org/10.1210/jc.2015-1818